Literature DB >> 11307152

Interleukin-10 gene promoter polymorphisms in multiple myeloma.

C Zheng1, D Huang, L Liu, R Wu, S Bergenbrant Glas, A Osterborg, M Björkholm, G Holm, Q Yi, A Sundblad.   

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow. It is unclear whether genetic background could have an etiological impact on MM or influence the course of the disease. Interleukin-10 (IL-10) has been implicated in the growth and differentiation of normal B cells, and has also been shown to enhance the proliferation of MM cells. To address the putative involvement of IL-10 genetic variation in MM, we analyzed previously defined loci for bi-allelic polymorphism at position -1082 and two microsatellite loci (IL10.G and IL10.R) in the IL-10 promoter region. Seventy-three patients with MM, 27 with monoclonal gammopathy of undetermined significance, and 109 ethnically matched individuals as controls were included in the study. Significantly increased frequencies of the IL10.G genotype 136/136 and the IL10.R genotype 112/114, in addition to a decreased frequency of the IL10.R genotype 114/116, were found among the MM patients. Increased production of IL-10 was detected in the supernatants of lipopolysaccharide-stimulated peripheral blood mononuclear cells from MM patients who were homozygotes (136/136) and heterozygotes (136/non-136) for the IL10.G allele 136, as compared with the other IL10.G genotype carriers (non-136/non-136). These results suggest that the genetic variation in the IL-10 promoter region may play a role in the development of MM. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307152     DOI: 10.1002/1097-0215(20010520)95:3<184::aid-ijc1031>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Interleukin-10 polymorphisms, cancer susceptibility and prognosis.

Authors:  W Martin Howell; Matthew J Rose-Zerilli
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis.

Authors:  Yong-Gang Wei; Fei Liu; Bo Li; Xi Chen; Yu Ma; Lv-Nan Yan; Tian-Fu Wen; Ming-Qing Xu; Wen-Tao Wang; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

3.  Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.

Authors:  H Dean Hosgood; Dalsu Baris; Yawei Zhang; Sonja I Berndt; Idan Menashe; Lindsay M Morton; Kyoung-Mu Lee; Meredith Yeager; Shelia H Zahm; Stephen Chanock; Tongzhang Zheng; Qing Lan
Journal:  Leuk Res       Date:  2009-04-11       Impact factor: 3.156

4.  Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs.

Authors:  F Tian; J Li; Y Li; S Luo
Journal:  Blood Cancer J       Date:  2012-06-15       Impact factor: 11.037

5.  Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.

Authors:  Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Jedynak; Marek Kielbinski; Dariusz Woszczyk; Stanisław Potoczek; Anna Jonkisz; Kazimierz Kuliczkowski; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-07-09       Impact factor: 3.201

6.  Interleukin-10 genotype correlated to deficiency syndrome in hepatitis B cirrhosis.

Authors:  Qing-Ya Li; Zhi-Zhong Guo; Jian Liang; Wei Zhang; Lie-Ming Xu; Yue-Qiu Gao; Xiao-Su Wang; Dong-Ying Xue; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-28       Impact factor: 2.629

7.  Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2-myeloma cell interaction.

Authors:  Faqing Tian; Bo Lu; Ziren Chen; Junru Liu; Delan Ji; Juheng Li; Meiqin Tang; Wei Zhu; Juan Li
Journal:  BMC Cancer       Date:  2019-12-23       Impact factor: 4.430

8.  Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer.

Authors:  Yaw-Cheng Wang; Wen-Wei Sung; Tzu-Chin Wu; Lee Wang; Wen-Pin Chien; Ya-Wen Cheng; Chih-Yi Chen; Shwn-Huey Shieh; Huei Lee
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients.

Authors:  C Banu; A Moise; C V Arion; D Coriu; A Tănase; I Constantinescu
Journal:  J Med Life       Date:  2011-08-25

10.  Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.

Authors:  Brian Van Ness; Christine Ramos; Majda Haznadar; Antje Hoering; Jeff Haessler; John Crowley; Susanna Jacobus; Martin Oken; Vincent Rajkumar; Philip Greipp; Bart Barlogie; Brian Durie; Michael Katz; Gowtham Atluri; Gang Fang; Rohit Gupta; Michael Steinbach; Vipin Kumar; Richard Mushlin; David Johnson; Gareth Morgan
Journal:  BMC Med       Date:  2008-09-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.